Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Clinical trial NCT04504071 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04504071
Sponsor: Shanghai Chest Hospital
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer Metastatic EGF-R Positive Non-Small Cell Lung Cancer

Start date: 2020-12-08
Primary completion: 2022-12-15
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.